An improved understanding of the disease biology of leukemia has driven personalized therapy that has helped lower the risk of relapse in patients. Here, Patrick Kiel, PharmD, BCOP, BCPS, of Indiana University Simon Cancer Center, Indianapolis, IN, discusses a case study in which the patient was identified with PD-L1 expression and a BRAF V600E mutation, and how these identifications helped improve the treatment outcome. Dr Kiel was speaking at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.
Personalized therapy in leukemia: a case study
